Influenza Vaccines Market – By Vaccine Type (Inactivated, Live Attenuated), Indication (Quadrivalent, Trivalent), Technology (Egg-based, Cell-based), Flu Type (Seasonal, Pandemic), Age Group, Route of Administration, End-user, Global Forecast 2024 – 2032

Influenza Vaccines Market – By Vaccine Type (Inactivated, Live Attenuated), Indication (Quadrivalent, Trivalent), Technology (Egg-based, Cell-based), Flu Type (Seasonal, Pandemic), Age Group, Route of Administration, End-user, Global Forecast 2024 – 2032

Influenza Vaccines Market Size

Influenza Vaccines Market size was valued to be worth USD 7.1 billion in 2023 and is estimated to witness 6.8% CAGR from 2024 to 2032. The increasing prevalence of influenza, rising government health initiatives & immunization programs, and growing advancements in vaccine technology are the major factors responsible for the growth of this market.
 

For instance, during the 2021-2022 season, the Centers for Disease Control and Prevention reported a significant burden of influenza in the U.S., with an estimated 9.4 million flu cases. Among those, 4.3 million medical facility visits related to flu, 100,000 flu-related hospitalizations, and 4,900 flu-related deaths. This surge in influenza cases contributes to an increased demand for influenza vaccines, thereby fostering the market expansion.
 

Influenza vaccines, commonly known as flu vaccines, are preventive measures designed to protect individuals against influenza viruses. Influenza is a highly contagious respiratory illness caused by influenza viruses, and it can lead to severe illness or complications, especially in vulnerable populations such as the elderly and young children. The primary purpose of influenza vaccines is to stimulate the immune system to recognize and mount a defense against the influenza virus. These vaccines typically contain inactivated (killed) viruses, live attenuated (weakened) viruses.
 

Influenza Vaccines Market Trends

• Governments recognize the public health impact of influenza and the potential economic burden associated with flu-related healthcare costs and productivity losses. Consequently, several governments implement vaccination programs to provide free or subsidized influenza vaccines to specific demographics, such as the elderly, healthcare workers, and high-risk individuals. These programs aim to increase vaccination coverage, reduce the incidence of influenza-related complications, and support the growth of this market.
   
• Also, the development of quadrivalent vaccines that protect against four influenza strains instead of three has become more common. Therefore, the ongoing research and development efforts in vaccine technology contribute to improved efficacy, durability of protection, and patient compliance, driving the overall market demand.
   
• Furthermore, the increased utilization of influenza diagnostic tests and development of rapid influenza diagnostic tests has resulted in early diagnosis and eventually contributed to increased demand for these vaccines.
   

However, the high cost associated with vaccine development and longer vaccine production timelines may hamper the industry landscape.
 

Influenza Vaccines Market Analysis

Based on vaccine type, the global market is segmented into inactivated and live attenuated. The inactivated segment is projected to experience growth at 6.9% over the coming years.
 

• Inactivated influenza vaccines have a long history of proven safety and efficacy. They are approved for a wide age range demographics including children, adults, and the elderly. This versatility makes them suitable for mass vaccination campaigns, school-based programs, and other initiatives targeting diverse populations.
   
• Also, these vaccines are generally more stable and have a longer shelf life compared to some other types of vaccines. This characteristic simplifies storage and distribution logistics, especially in regions with challenging healthcare infrastructure, thereby contributing significantly to their prominence in the market.
   

Based on indication, the global influenza vaccines market is classified as quadrivalent and trivalent. The quadrivalent segment was valued at USD 6.2 billion 2023.
 

• Quadrivalent vaccines cover four influenza strains—two influenza A and two influenza B strains. This broader coverage is advantageous in providing protection against a more comprehensive array of circulating influenza viruses compared to trivalent vaccines.
   
• Further, the increasing adoption of quadrivalent vaccines due to higher efficacy against influenza B viruses, which are more common in children, enhanced strain coverage, easy availability in healthcare facility, and consistent vaccine composition contributes to the segment progress.

Based on technology, the global influenza vaccines market is categorized into egg-based and cell-based. The egg-based segment is anticipated to reach USD 10.8 billion by 2032.
 

• Egg-based vaccine production has been a longstanding and well-established method in the industry. Several vaccine manufacturers have invested heavily in egg-based infrastructure, making it a widely adopted and reliable production method.
   
• Further, egg-based production methods allow for large-scale vaccine manufacturing, making them suitable for meeting the demand during peak influenza seasons or in the event of pandemics. These factors collectively aid in highest growth of egg-based segment.
   

Based on flu type, the global influenza vaccines market is divided into seasonal and pandemic. The seasonal segment accounted for largest business share of 72.4% in 2023.
 

• Seasonal influenza vaccines are administered annually as part of routine vaccination programs. This regularity creates a consistent and predictable demand for these vaccines, contributing to their high market share.
   
• Moreover, seasonal influenza outbreaks can strain healthcare systems, leading to increased hospitalizations and medical visits. Therefore, influenza vaccination helps minimize the burden on healthcare facilities by preventing a significant number of influenza-related cases and reducing the overall demand for medical care.
   

Based on age group, the influenza vaccines market is bifurcated into adults and pediatrics. The adult segment is estimated to be valued at USD 10.5 billion by 2032 with CAGR of 7.3%.
 

• Adults generally experience a higher disease burden and more severe complications from influenza compared to other age groups. As a result, there is a greater emphasis on vaccinating adults to reduce the impact of influenza on public health.
   
• Also, many health authorities and organizations recommend influenza vaccination for specific high-risk groups, including adults aged 65 and older, pregnant women, individuals with certain medical conditions, and healthcare workers. Hence, these recommendations drive higher vaccination rates among adults, thereby augmenting the segment expansion.
   

Based on route of administration, the global influenza vaccines market is segmented into injection and nasal spray. The injection segment dominated the market in 2023 and is expected to show similar trend during the analysis period.

• Intramuscular or subcutaneous injections are a well-established and widely accepted route of vaccine administration. They are routinely administered in healthcare settings, making them a convenient and preferred method for influenza vaccination.
   
• Furthermore, the proven safety and efficacy, global regulatory approval, stability of vaccine formulation, high patient compliance, and ability to administer to a diverse population are factors supporting the growth of this segment.
   

Based on end-user, the global influenza vaccines market is divided into hospitals, clinics, and other end-users. The hospitals segment accounted for highest revenue share of 72.8%.

• Hospitals are widely accessible to the general population. Individuals can easily receive influenza vaccines during routine visits to healthcare facilities or when picking up prescriptions at pharmacies, enhancing convenience and accessibility.
   
• Further, these healthcare settings benefit from established infrastructure along with the presence of trained healthcare professionals, collaboration with public health campaigns, and insurance coverage.

The North America influenza vaccines market is anticipated to grow at CAGR 6.5% and is expected to dominate the market throughout the forthcoming years.
 

• The region boasts a well-established healthcare infrastructure with numerous hospitals, clinics, and pharmacies. This infrastructure facilitates the distribution and administration of influenza vaccines, ensuring accessibility for a large population. Also, market is experiencing steady growth, largely due to the increasing adoption of strategies by major players in the region.
   
• Further, there is generally high awareness and education about the importance of vaccination in North America. Public health campaigns, educational initiatives, and a proactive approach to preventive healthcare contribute to the region's high market expansion.
   

Influenza Vaccines Market Share

The influenza vaccines industry is characterized by the active participation of key pharmaceutical companies and biotech firms striving to address the public health challenges posed by seasonal and pandemic influenza. Leading players such as Sanofi, GlaxoSmithKline (GSK), CSL Limited have established themselves as major contributors to the market, offering a range of trivalent and quadrivalent influenza vaccines. The market continues to evolve, the competitive landscape is likely to be shaped by ongoing advancements, regulatory considerations, and responses to emerging infectious threats.
 

Influenza Vaccines Market Companies

Key leaders operating in the influenza vaccines industry are as mentioned below

• AstraZeneca plc
• CSL Limited
• Emergent Biosolutions
• Gamma Vaccines Pty Ltd.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Sinovac Biotech Ltd.
• Viatris Inc.
   

Influenza Vaccines Industry News

• In October 2023, U.S. Food and Drug Administration accepted AstraZeneca application for review seeking approval of its nasal flu vaccine branded as FluMist Quadrivalent. This strategic initiative is expected to help the company to expand its business portfolio.
   
• In July 2022, U.S. Food and Drug Administration approved Fluzone- High-Dose Quadrivalent (Influenza Vaccine) and Flublok- Quadrivalent (Influenza Vaccine) of Sanofi for 2022-2023 influenza season. The product approval aimed to diversify its influenza product portfolio, thereby strengthening its market position.
   

The influenza vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments

Click here to Buy Section of this Report

Market, By Vaccine Type

• Inactivated
• Live attenuated

Market, By Indication

• Quadrivalent
• Trivalent

Market, By Technology

• Egg-based
• Cell-based

Market, By Flu Type

• Seasonal
• Pandemic

Market, By Age Group

• Pediatrics
• Adults

Market, By Route of Administration

• Injection
• Nasal spray

Market, By End-user

• Hospitals
  • Public
  • Private 
• Clinics
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa